The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Investors in Conatus, and especially those in Newlink, should question how valuations of the groups' reversing acquirers have been calculated.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.